Abstract: A skin sample culture apparatus which has a base frame, with a skin sample receiving surface upon which at least part of the skin sample may be placed and which extends across an area defined by the shape of the frame. A securing member which is releasably connectable to the base frame and a grip which holds the skin sample under tension. The apparatus may include a tensioner to hold the sample under tension and means for introducing a fluid to the upper or lower surface of the sample.

Abstract: An actuator (1) is described having a first part (4), a second part (2), and a body portion (3) between the first and second parts, wherein the body portion includes at least one chamber (14) configured to be pressurised and the body portion has a longitudinal axis; and a plurality of cables (6,7,8,9), wherein each of the plurality of cables is arranged in a respective at least partial spiral with respect to the longitudinal axis of the body portion (3); and wherein the plurality of cables are arranged such that the application of a selected force to at least one of the cables causes a desired movement of the first part relative to the second part.

Abstract: Compounds having the general structure A-L-B are presented wherein A and B are independently an E3 ubiquitin ligase protein binding ligand compound of formula 1A or 1B. Pharmaceutical compositions comprising these compounds and methods of use are also presented.

Abstract: The present invention relates to the production of activated biological molecules for use in profiling biological molecule interactions. The activated biological molecule may be a ubiquitin (Ub) and ubiquitin-like conjugation enzyme as well as other proteins with internal reactive cysteine residues.

Abstract: There is provided novel small molecule E3 ubiquitin ligase protein binding ligand compounds, and to their utility in PROteolysis Targeted Chimeras (PROTACs), as well as processes for their preparation thereof, and use in medicine. There is particularly provided novel small molecule E3 ubiquitin ligase protein binding inhibitor compounds based on a fluorohydroxyproline scaffold, to their utility as ligands in synthesizing novel PROTACs, and to synthetic methods therefor.

Abstract: There is provided novel small molecule E3 ubiquitin ligase protein binding ligand compounds, having utility in PROteolysis Targeted Chimeras (PROTACs), as well as processes for the preparation thereof, and use in medicine. There is particularly provided PROTACs which bind to a protein within the bromo- and Extra-terminal (BET) family of proteins, and especially to PROTACs including novel small molecule E3 ubiquitin ligase protein binding ligand compounds which selectively induce degradation of the BRD4 protein within the bromodomain of the BET family of proteins.

Abstract: The patent describes the innovation that allows users to virtually try clothes on their 3D-models. The system uses photogrammetry to construct a 3D projection from images followed by modeling and character building. The body measures are derived from 3D constructions. The innovation lets users build their 3D characters from 3D-models that has applications like academic, research, 3D printing, designing decorative items, and digital media. The system provides a RESTful service that allows webmasters to send the cloth dimensions and with user identifier through a web client. The system identifies the user from the identifier and compares the dimensions of the user body and clothes and try to perform a virtual fitting generating the fitting information. Both character and fitting information are sent to the web client that displays the fitting information mapped on the character on a 3D viewer.

Abstract: A method of blackening a surface, comprises applying laser radiation to the surface of a target (10) to produce a periodic arrangement of structures on the surface of the target (10), wherein the laser radiation comprises pulsed laser radiation comprising a series of laser pulses and the power density of the pulses is in a range 2 GW/cm2 to 50 GW/cm2 or 0.1 TW/cm2 to 3 TW/cm2, and/or a pulse duration between 200 femtoseconds to 1000 picoseconds.

Abstract: An actuator includes first and second ends defining an axis there between, and at least four inflatable chambers. Each inflatable chamber is resiliently deformable, elongate, and extends axially between the first and second ends and circumferentially about a central core defined between the ends and by the inflatable chambers. A first pair of the four inflatable chambers is contra rotatory about the core to a second pair of the four inflatable chambers. A pressure change in one or more of the inflatable chambers causes motion of the first end relative to the second end. The actuators can be employed in robots or robotic arms.

Abstract: A compound of Formula (I), or a salt thereof, compositions comprising the compound, processes for its preparation and its use in therapy, for example in the treatment of parasitic diseases such as Chagas disease, Human African Trypanosomiasis (HAT), Animal African trypanosomiasis (AAT) and leishmaniasis, particularly visceral leishmaniasis (VL).

Abstract: A medical instrument has a tubular shaft, a handle at a proximal end of the shaft and a movable working part at a distal end of the shaft, the shaft includes a shaft section having a curvature and being arranged between the distal end and the proximal end of the shaft. The handle and the working part are operatively connected via a force transmission element extending through the shaft. The force transmission element has a section arranged within the curved shaft section of the shaft, the section being guided on an inner surface of the shaft and having a plurality of interconnected single elements arranged one after the other along the longitudinal direction of the shaft. The single elements are pairwise connected by a pin forming a hinged joint, such that each of the pins defines a rotation axis oriented substantially perpendicular relative to the shaft.

Abstract: The compound 3,3,3-trifluoro-N-((1,4-trans)-4-((3-((S)-2-methylmorpholino)-IH-pyrazolo[3,4-d]pyrimidin-6-yl)amino)cyclohexyl)propane-1-sulfonamide having the Formula (I) or a salt thereof, its opposite enantiomer, compositions comprising the compound and its use in the treatment or prevention of leishmaniasis, particularly visceral leishmaniasis.

Abstract: A method of reducing photoelectron yield (PEY) and/or secondary electron yield (SEY) of a ceramic surface comprises applying pulsed laser radiation comprising a series of laser pulses emitted by a laser (4) to the surface of a target (10) to produce a periodic arrangement of structures on the surface of the target (10).

Abstract: The present invention relates to the discovery that salt inducible kinases (SIKs) suppress the formation of anti-inflammatory molecules such as IL-10, which are important for the resolution of inflammation and identifies SIK inhibitors that may be used to treat disorders associated with undesirable inflammation, such as inflammatory bowel disease and/or autoimmune disorders.

Abstract: A compound of Formula (I), or a salt thereof, compositions comprising the compound, processes for its preparation and its use in therapy, for example in the treatment of parasitic diseases such as Chagas disease, Human African Trypanosomiasis (HAT) and leishmaniasis, particularly visceral leishmaniasis (VL).

Abstract: The present invention relates to the discovery that salt inducible kinases (SIKs) suppress the formation of anti-inflammatory molecules such as IL-10, which are important for the resolution of inflammation and identifies SIK inhibitors that may be used to treat disorders associated with undesirable inflammation, such as inflammatory bowel disease and/or autoimmune disorders.

Abstract: The present invention provides a compound having the structure: wherein X is C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, cyano, aryl, heteroaryl, alkylaryl, alkylheteroaryl, alkenylaryl, alkenylheteroaryl, alkynylaryl, alkynylheteroaryl, alkoxy, alkenyloxy, alkynyloxy, aryloxy, heteroaryloxy, acyl, alkylhydroxy, alkylamino, alkenylamino, alkynylamino, amido, carboxyl, or carboxyl ester, or forms an unsubstituted or substituted cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, indane or tetralin with Y, Y is H or forms an unsubstituted or substituted cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, indane or tetralin with X, or forms an unsubstituted or substituted monocycle with Z; and Z is H or forms an unsubstituted or substituted monocycle with Y; wherein when X and Y are both H, then X is C2alkenyl or C2 alkynyl, and when Y is H forms a substituted cyclohexyl, cycloheptyl with X, the cyclohexyl is other than a trisubstituted cyclohexyl bearing CH3, i-Pr and (CH2)2CO2CH3 groups or CH3, i-Pr and (C

Abstract: The present invention provides methods and compositions for modulating cell senescence and cell proliferation using isoforms of the p53 tumor suppressor protein. The methods and compositions of the invention find use in inhibiting cancer cell growth or in generating populations of cells for tissue regeneration through the modulation of cell senescence and proliferation.

Abstract: The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.

Abstract: The disclosure is based on the discovery of genes which influence lignin biosynthesis. In particular, the inventors have observed that if the expression, function and/or activity of these gene(s) (or any protein products thereof) is/are modulated, the lignin content of plants can be altered. As such, this disclosure provides plants, which exhibit modulated expression of one or more lipase/esterase/thioesterase family gene(s) and which may find application in methods for producing biofuels.